0001516551-24-000043.txt : 20240304
0001516551-24-000043.hdr.sgml : 20240304
20240304195344
ACCESSION NUMBER: 0001516551-24-000043
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240229
FILED AS OF DATE: 20240304
DATE AS OF CHANGE: 20240304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Grayson Paul A.
CENTRAL INDEX KEY: 0001861554
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-55136
FILM NUMBER: 24717697
MAIL ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Skye Bioscience, Inc.
CENTRAL INDEX KEY: 0001516551
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 450692882
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11250 EL CAMINO REAL, SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 410-0266
MAIL ADDRESS:
STREET 1: 11250 EL CAMINO REAL, SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Emerald Bioscience, Inc.
DATE OF NAME CHANGE: 20190325
FORMER COMPANY:
FORMER CONFORMED NAME: Nemus Bioscience, Inc.
DATE OF NAME CHANGE: 20141030
FORMER COMPANY:
FORMER CONFORMED NAME: LOAD GUARD LOGISTICS, INC.
DATE OF NAME CHANGE: 20121107
4
1
wk-form4_1709600012.xml
FORM 4
X0508
4
2024-02-29
0
0001516551
Skye Bioscience, Inc.
SKYE
0001861554
Grayson Paul A.
C/O SKYE BIOSCIENCE, INC.
1250 EL CAMINO REAL SUITE 100
SAN DIEGO
CA
92130
1
0
0
0
0
Common Stock
2024-02-29
4
A
0
100000
0
A
346252
D
Stock Option (Right to Buy)
14.56
2024-02-29
4
A
0
35000
0
A
2034-03-01
Common Stock
35000
35000
D
Represents a restricted stock unit ("RSU") award that vests on the following milestones: 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest upon achieving a market cap of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the RSUs will become fully vested.
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
2024-03-04